公开(公告)号：EP3520799A1

公开(公告)日：2019-08-07

申请号：EP18155278.7

申请日：2018-02-06

申请人： European Molecular Biology Laboratory

发明人： Tramontano, Melanie ,  Klünemann, Martina ,  Pruteanu, Mihaela ,  Maier, Lisa ,  Kuhn, Michael ,  Andrejev, Sergej ,  Kim, Yongkyu ,  Bork, Peer ,  Typas, Athanasios ,  Patil, Kiran Raosaheb ,  Zeller, Georg

IPC分类号： A61K35/00 ,  C12N1/20

摘要： The present invention relates to an in-vitro model of the human gut microbiome, the model comprising a culture of the gut microbiome, wherein the model has a cumulative enzymatic coverage of more than 85% of the gut microbiome of a healthy human. The model facilitates metabolic modeling and enables a better understanding of the structure and function of the human gut microbiome as well as of modifications of xenobiotics by intrinsic gut microbiota, such as biotransformation and bioaccumulation. It can further be used to study the effects of variations in nutritional conditions. Importantly, the invention can also be used for diagnosing a disease, such as a gastrointestinal disorder, a proliferative disease, a metabolic disorder, a cardiovascular disease, an immunological disease, and an infectious disease.

公开(公告)号：EP3838269A1

公开(公告)日：2021-06-23

申请号：EP19216548.8

申请日：2019-12-16

申请人： European Molecular Biology Laboratory

发明人： Typas, Athanasios ,  Maier, Lisa ,  Goemans, Camilie ,  Gontao Brochado, Ana Rita ,  Cacace, Elisabetta

IPC分类号： A61K31/00 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  A61P1/00 ,  A61P1/14 ,  A61K31/05 ,  A61K31/343 ,  A61K31/37 ,  A61K31/7056 ,  A61K31/196 ,  A61K31/197 ,  A61K31/4152

摘要： The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

公开(公告)号：EP3560489A1

公开(公告)日：2019-10-30

申请号：EP18169989.3

申请日：2018-04-27

申请人： European Molecular Biology Laboratory

发明人： Gontao Brochado, Ana Rita ,  Typas, Athanasios ,  Göttig, Stephan

IPC分类号： A61K31/11 ,  A61K31/12 ,  A61K31/395 ,  A61K31/7036 ,  A61P31/04

摘要： The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.